Cover Image
市場調查報告書

肛門癌:開發平台分析

Anal Cancer - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213060
出版日期 內容資訊 英文 198 Pages
訂單完成後即時交付
價格
Back to Top
肛門癌:開發平台分析 Anal Cancer - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 198 Pages
簡介

肛門癌發生於肛門,常見的症狀有直腸出血,直腸發癢,肛門開口部腫瘤和疙瘩,肛門周圍會感到疼痛和腫。原因有人類乳突病毒的感染和抽煙,免疫力低落等。

本報告提供肛門癌的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃相關資訊等,同時加上最新的新聞和發表等資料。

簡介

  • 調查範圍

肛門癌 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業正在開發的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥開發作的企業

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9656IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H2 2017, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 3 and 4 respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anal Cancer - Overview
    • Anal Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Anal Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Anal Cancer - Companies Involved in Therapeutics Development
    • Advaxis Inc
    • Amgen Inc
    • Atara Biotherapeutics Inc
    • Bayer AG
    • BeiGene Ltd
    • Eli Lilly and Company
    • Immunovaccine Inc
    • ISA Pharmaceuticals BV
    • Merck & Co Inc
    • Ono Pharmaceutical Co Ltd
    • Oryx GmbH & Co KG
    • PDS Biotechnology Corp
    • Sun Pharma Advanced Research Company Ltd
    • Taiwan Liposome Company Ltd
  • Anal Cancer - Drug Profiles
    • ATA-368 - Drug Profile
    • axalimogene filolisbac - Drug Profile
    • axalimogene filolisbac second generation - Drug Profile
    • BAY-1125976 - Drug Profile
    • BGBA-317 - Drug Profile
    • cisplatin - Drug Profile
    • CUE-101 - Drug Profile
    • DPXE-7 - Drug Profile
    • ISA-101 - Drug Profile
    • nivolumab - Drug Profile
    • paclitaxel albumin free - Drug Profile
    • panitumumab - Drug Profile
    • PDS-0101 - Drug Profile
    • pembrolizumab - Drug Profile
    • prexasertib - Drug Profile
    • TLC-388 - Drug Profile
    • Vicoryx - Drug Profile
  • Anal Cancer - Dormant Projects
  • Anal Cancer - Discontinued Products
  • Anal Cancer - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Anal Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Anal Cancer - Pipeline by Advaxis Inc, H2 2017
  • Anal Cancer - Pipeline by Amgen Inc, H2 2017
  • Anal Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017
  • Anal Cancer - Pipeline by Bayer AG, H2 2017
  • Anal Cancer - Pipeline by BeiGene Ltd, H2 2017
  • Anal Cancer - Pipeline by Eli Lilly and Company, H2 2017
  • Anal Cancer - Pipeline by Immunovaccine Inc, H2 2017
  • Anal Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017
  • Anal Cancer - Pipeline by Merck & Co Inc, H2 2017
  • Anal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
  • Anal Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017
  • Anal Cancer - Pipeline by PDS Biotechnology Corp, H2 2017
  • Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
  • Anal Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017
  • Anal Cancer - Dormant Projects, H2 2017
  • Anal Cancer - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Anal Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top